FDA drops mandatory clozapine monitoring, but clinician hesitancy persists
The FDA has eliminated the compulsory registry that required weekly blood tests for clozapine, a drug vital for treatment-resistant schizophrenia, yet many doctors remain reluctant to prescribe it, especially for children.
The Food and Drug Administration announced on Feb. 24, 2025 that it would no longer require clinicians to enroll patients in a national registry and submit weekly blood-count results before dispensing clozapine. Clozapine remains the most effective antipsychotic for the roughly one-third of schizophrenia patients who do not respond to other treatments, and it is the only drug proven to lower suicide rates. Historically, the mandatory monitoring program was intended to catch rare cases of neutropenia, but critics say it has also kept many eligible patients, especially children with early-onset schizophrenia, from receiving the drug.
Psychiatrist Nitin Gogtay notes that fear of side effects, rather than paperwork, drives the continued underuse. He points to research showing that strategies such as adding lithium can mitigate blood-cell risks, and that clinicians should rely on informed judgment instead of regulatory mandates. The FDA still recommends regular blood testing, but the decision shifts responsibility to doctors and patients, offering an opportunity to treat severe cases earlier rather than as a last resort.
Why it matters
Removing the FDA's clozapine registry could increase access to a life-saving drug for severe schizophrenia, but clinician fear may still limit its use.
In this story
